| Dr Brett D Young, MD | |
|
1405 Mill St, New London, WI 54961-2155 | |
| (920) 831-5050 | |
| (920) 738-6400 |
| Full Name | Dr Brett D Young |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 27 Years |
| Location | 1405 Mill St, New London, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770578189 | NPI | - | NPPES |
| 34203900 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 44471 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Thedacare Medical Center - New London | New london, WI | Hospital |
| Thedacare Medical Center - Shawano | Shawano, WI | Hospital |
| Thedacare Regional Medical Center - Appleton Inc | Appleton, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Thedacare Incorporated | 1759294887 | 493 |
News Archive
"This won't go on for very long," Sharon Hall said to herself when she invited her elderly mother, who'd suffered several small strokes, to live with her.
A Chinese caterpillar fungus that is used in traditional Chinese medicine has been found to minimize motor neuron loss in mice models of ALS.
Back just 100 years ago, the notion of testing treatments and drugs through randomized clinical trials was unheard of. Clinical trials began to proliferate only in 1800, placebos were first used in 1863 and randomization wasn't introduced until 1923.
Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
› Verified 2 days ago
| Entity Name | Thedacare Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376656959 PECOS PAC ID: 1759294887 Enrollment ID: O20031106000088 |
News Archive
"This won't go on for very long," Sharon Hall said to herself when she invited her elderly mother, who'd suffered several small strokes, to live with her.
A Chinese caterpillar fungus that is used in traditional Chinese medicine has been found to minimize motor neuron loss in mice models of ALS.
Back just 100 years ago, the notion of testing treatments and drugs through randomized clinical trials was unheard of. Clinical trials began to proliferate only in 1800, placebos were first used in 1863 and randomization wasn't introduced until 1923.
Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brett D Young, MD 3 Neenah Ctr, Neenah, WI 54956-3070 Ph: (920) 831-5050 | Dr Brett D Young, MD 1405 Mill St, New London, WI 54961-2155 Ph: (920) 831-5050 |
News Archive
"This won't go on for very long," Sharon Hall said to herself when she invited her elderly mother, who'd suffered several small strokes, to live with her.
A Chinese caterpillar fungus that is used in traditional Chinese medicine has been found to minimize motor neuron loss in mice models of ALS.
Back just 100 years ago, the notion of testing treatments and drugs through randomized clinical trials was unheard of. Clinical trials began to proliferate only in 1800, placebos were first used in 1863 and randomization wasn't introduced until 1923.
Exelixis, Inc. today announced final results from BRIM7, an ongoing phase 1b clinical trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor cobimetinib in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
› Verified 2 days ago
Terry J Dietrich, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 1405 Mill St, New London, WI 54961 Phone: 920-831-5050 |